MA28815B1 - Derives de indole-2-carboxamidine utilises comme antagonistes du recepteur nmda - Google Patents

Derives de indole-2-carboxamidine utilises comme antagonistes du recepteur nmda

Info

Publication number
MA28815B1
MA28815B1 MA29702A MA29702A MA28815B1 MA 28815 B1 MA28815 B1 MA 28815B1 MA 29702 A MA29702 A MA 29702A MA 29702 A MA29702 A MA 29702A MA 28815 B1 MA28815 B1 MA 28815B1
Authority
MA
Morocco
Prior art keywords
indole
antagonists
nmda receptor
carboxamidine derivatives
carboxamidine
Prior art date
Application number
MA29702A
Other languages
English (en)
French (fr)
Inventor
Istvan Borza
Csilla Horvath
Sandor Farkas
Jozsef Nagy
Sandor Kolok
Original Assignee
Richter Gedeon Vegyeszet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet
Publication of MA28815B1 publication Critical patent/MA28815B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
MA29702A 2004-07-29 2007-02-22 Derives de indole-2-carboxamidine utilises comme antagonistes du recepteur nmda MA28815B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0401523A HUP0401523A3 (en) 2004-07-29 2004-07-29 Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them

Publications (1)

Publication Number Publication Date
MA28815B1 true MA28815B1 (fr) 2007-08-01

Family

ID=89985408

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29702A MA28815B1 (fr) 2004-07-29 2007-02-22 Derives de indole-2-carboxamidine utilises comme antagonistes du recepteur nmda

Country Status (21)

Country Link
US (1) US20090048303A1 (enExample)
EP (1) EP1773770B1 (enExample)
JP (1) JP2008508248A (enExample)
KR (1) KR20070038502A (enExample)
CN (1) CN1989103A (enExample)
AP (1) AP2006003840A0 (enExample)
AT (1) ATE427299T1 (enExample)
AU (1) AU2005266160A1 (enExample)
BR (1) BRPI0513932A (enExample)
CA (1) CA2574155A1 (enExample)
DE (1) DE602005013675D1 (enExample)
EA (1) EA009981B1 (enExample)
GE (1) GEP20094606B (enExample)
HU (1) HUP0401523A3 (enExample)
IL (1) IL179485A0 (enExample)
MA (1) MA28815B1 (enExample)
MX (1) MX2007001052A (enExample)
NO (1) NO20071109L (enExample)
TN (1) TNSN07016A1 (enExample)
WO (1) WO2006010965A1 (enExample)
ZA (1) ZA200700325B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
EP2142514B1 (en) 2007-04-18 2014-12-24 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
CA2788656A1 (en) 2010-02-16 2011-08-25 Pfizer Inc. (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
NZ602312A (en) 2010-03-10 2014-02-28 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
SG10201510402WA (en) * 2010-11-18 2016-01-28 Univ Yale Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP2852588B8 (en) * 2012-05-22 2018-01-10 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
JP7114594B2 (ja) 2017-07-28 2022-08-08 武田薬品工業株式会社 複素環化合物
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726388D0 (en) * 1997-12-12 1998-02-11 Cerebrus Ltd Chemical compounds
US6376530B1 (en) * 1999-05-10 2002-04-23 Merck & Co., Inc. Cyclic amidines useful as NMDA NR2B antagonists
US6319944B1 (en) * 1999-05-10 2001-11-20 Merck & Co., Inc. Aryl amidines, compositions containing such compounds and methods of use
GB0015488D0 (en) * 2000-06-23 2000-08-16 Merck Sharp & Dohme Therapeutic agents
HU227197B1 (en) * 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
JP2004253425A (ja) * 2003-02-18 2004-09-09 Tdk Corp 積層コンデンサ

Also Published As

Publication number Publication date
KR20070038502A (ko) 2007-04-10
HUP0401523A3 (en) 2007-05-02
WO2006010965A1 (en) 2006-02-02
HUP0401523A2 (en) 2006-11-28
DE602005013675D1 (de) 2009-05-14
EP1773770B1 (en) 2009-04-01
EP1773770A1 (en) 2007-04-18
EA200700365A1 (ru) 2007-06-29
CN1989103A (zh) 2007-06-27
NO20071109L (no) 2007-02-27
TNSN07016A1 (en) 2008-06-02
EA009981B1 (ru) 2008-04-28
IL179485A0 (en) 2007-05-15
AU2005266160A1 (en) 2006-02-02
ZA200700325B (en) 2008-05-28
US20090048303A1 (en) 2009-02-19
ATE427299T1 (de) 2009-04-15
BRPI0513932A (pt) 2008-05-20
JP2008508248A (ja) 2008-03-21
MX2007001052A (es) 2007-04-16
CA2574155A1 (en) 2006-02-02
GEP20094606B (en) 2009-02-10
HU0401523D0 (en) 2004-09-28
AP2006003840A0 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
MA28815B1 (fr) Derives de indole-2-carboxamidine utilises comme antagonistes du recepteur nmda
EP2049110A4 (en) BRAZED DIAZEPANOREXINE RECEPTOR ANTAGONISTS
EP2004654A4 (en) Kinase Antagonists
EP2344497A4 (en) AZAINDOL DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS
DK2094690T3 (da) 2-aza-bicyclo[3.1.0]hexanderivater som orexinreceptorantagonister
PT2570128T (pt) Antagonistas do receptor muscarínico de acetilcolina
EP2013169A4 (en) INDOLAMID DERIVATIVES AS ANTAGONISTS OF THE EP4 RECEPTOR
PL2046775T3 (pl) Pochodne N-(amino-heteroarylo)-1H-indolo-2-karboksamidów będących antagonistami wobec receptorów typu TRPV1 lub VR1
FR20C1027I2 (fr) Derives de tiglien-3-one
DK1735304T3 (da) Quinolinoncarboxamidforbindelser som 5-HT4-receptoragonister
CL2007001040A1 (es) Proceso para la preparacion de antagonista de la sustancia p derivado de acil-amino-alquilen-amida.
EP1973405A4 (en) HYDROXYALKYLARYLAMID DERIVATIVES
EP1915372A4 (en) INDOIND DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS
EP2346865A4 (en) INDOIND DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS
EP1807076A4 (en) N- (PYRIDIN-3-YL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS
EP2170064A4 (en) 6,5-pyrrolopiperidine tachykinin receptor antagonists
DK2402005T3 (da) Formuleringer med langvarig frigivelse af nalbuphin
EP1871752A4 (en) ANTAGONISTS OF THE AMIDOPROPOXYPHENYLOREXIN RECEPTOR
ATE382034T1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
DK1904477T3 (da) Indol-3-carbonyl-spiro-piperodom-derivater som V1A-receptorantagonister
DK1943242T3 (da) Piperidin-4-yl-pyridazin-3-ylamin-derivater som hurtigt opløsende antagonister af dopamin-2-receptorer
MA28686B1 (fr) Derives de pyrrolopyridine
DK1833791T3 (da) 2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
EP2125724A4 (en) NAPHTHALIN AND CHINOLIN SULFONYL HARVESIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS